A53T-MUTATED HUMAN Α-SYNUCLEIN IS INVOLVED IN BLOOD GLUCOSE REGULATION OF WESTERN TYPE DIET-FED PARKINSON’S DISEASE MICE
Magdalena Daurer1,2, Roland Rabl1, Heinrich Roemer2, Birgit Hutter-Paier1
IN VITRO AND IN VIVO MODELING OF MUTATED A53T ALPHA-SYNUCLEIN PATHOLOGY
Tina Loeffler, Roland Rabl, Irene Schilcher, Magdalena Daurer, Stefanie Flunkert, Birgit Hutter-Paier
REPURPOSING OF THE ANTI-ASTHMATIC DRUG MONTELUKAST FOR THE TREATMENT OF PARKINSON’S DISEASE
Katharina Strempfl1,2,3, Michael S. Unger2,3, Ludwig Aigner2,3, Jörg Neddens1, Stefanie Flunkert1, Birgit Hutter-Paier1
COMPARISON OF TWO DIFFERENT IN VITRO MODELS OF NEUROINFLAMMATION: CYTOKINE RELEASE AND INFLAMMASOME ACTIVATION IN ORGANOTYPIC SLICES AND BV2 CELLS
Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier
TREATMENT OF APPSL TRANSGENIC MICE WITH AN ALDH2 ACTIVATOR AS A PROMISING TREATMENT OPTION FOR ALZHEIMER’S DISEASE
Barbara Hinteregger1,2, Stefanie Flunkert1, Tobias Madl2, Joerg Neddens1, Wenjin Yang3 and Birgit Hutter-Paier1
CHARACTERIZATION OF 4L/PS-NA MICE FOR CYTOKINE ACTIVITY AND NEURODEGENERATION
Tina Loeffler, Ewald Auer, Irene Schilcher, Birgit Hutter-Paier
Tina Loeffler, Ph. D. will be taking part in a Live Q&A on Thursday, February 11 from 2:30-3:30pm EST
EVALUATION OF CD45 POSITIVE CELLS IN THE BRAIN AND LIVER OF NPC1-/- MICE
Magdalena Daurer, Ewald Auer, Joerg Neddens, Birgit Hutter-Paier
Magdalena Dauerer, Ph.D. will be taking part in a Live Q&A on Thursday, February 11 from 2:30-3:30pm EST
BIOANALYTICAL MONITORING OF GENE THERAPY TRIALS: METHODOLOGIES FOR PK PROFILING OF OLIGONUCLEOTIDES
Fabrizia Fusetti1, Zamas Lam2, Monique Putman1, Susan Zondlo2, Brad Yuska2, Lakshmi Ramanathan2, Tim Snow2
APPLICATION OF LC-HRMS IN PHARMACOKINETICS AND METABOLISM OF OLIGONUCLEOTIDES
Helen Shen, Ph.D.
Poster Time: Tuesday, Jan. 21st at 1:00-1:35 p.m.
Helen Shen, Ph.D., will be giving a presentation on Tuesday, January 21st at 1:00-1:35 p.m. at the Sheraton Bucks County Langhorne about the topic of the poster.
DEVELOPMENT AND VALIDATION OF A TRASTUZUMAB/PERTUZUMAB HYBRID LC-MS ASSAY FOR CLINICAL DEVELOPMENT
Fabrizia Fusetti, Ph.D.
Fabrizia Fusetti, Ph.D. will be making a presentation on Day 2, 18 November 2020 14:30-14:50.
STRATEGIES FOR THE PREVENTION OF NON-SPECIFIC BINDING IN THE QUANTITATIVE DETERMINATION OF DRUGS IN CEREBROSPINAL FLUID
Martijn Hilhorst, Robbert Edens, Bert Ottjes, Benjamin Steenge and Ben van Baar
DEVELOPMENT OF A HYBRID METHOD FOR SIMULTANEOUS QUANTIFICATION OF TWO NEAR IDENTICAL PROTEINS IN PLASMA
Chris Williams, Thomas Fokkinga, Francesco Bonardi, Fabrizia Fusetti and Martijn Hilhorst
NEUROFILAMNENT-LIGHT CHAIN IN MURINE MODELS OF NEURODEGENERATIVE AND RARE DISEASES
Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier
INFLAMMASOME ACTIVATION AND REDUCED sTREM2 RELEASE IN LPS STIMULATED ORGANOTYPIC BRAIN SLICES
Irene Schilcher, Tina Loeffler, Stefanie Flunkert, Birgit Hutter-Paier
CORRELATION OF Aβ-pE(3) AND ptau IN HUMAN AND MOUSE BRAIN
Magdalena Temmel1, Joerg Neddens1, Stefanie Flunkert1, Lauren Walker2, Johannes Attems2, Birgit Hutter-Paier1
2Translational and Clinical Research Institute and Newcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK
